Inventor · disambiguated record
Tatsuhiko Tachibana
Also filed as: TACHIBANA TATSUHIKO
20 granted patents·28 pending applications·518 citations·filing 2007–2025
96Inventor score
Top patents by PatentIndex Score
48 records- 0198US12122840B2Method of modifying isoelectric point of antibody via amino acid substitution in CDRCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Granted Oct 22, 2024·5 cites·24 claims
- 0298US12116414B2Method of modifying isoelectric point of antibody via amino acid substitution in CDRCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Granted Oct 15, 2024·5 cites·21 claims
- 0398US9828429B2Method of modifying isoelectric point of antibody via amino acid substitution in CDRCHUGAI PHARMACEUTICAL CO LTD·Filed 2015·Granted Nov 28, 2017·40 cites·80 claims
- 0498US9096651B2Method of modifying isoelectric point of antibody via amino acid substitution in CDRIGAWA TOMOYUKI·Filed 2008·Granted Aug 4, 2015·90 cites·44 claims
- 0598US8562991B2Antibody molecules that bind to IL-6 receptorIGAWA TOMOYUKI·Filed 2009·Granted Oct 22, 2013·130 cites·19 claims
- 0697US11248053B2Method of modifying isoelectric point of antibody via amino acid substitution in CDRCHUGAI PHARMACEUTICAL CO LTD·Filed 2017·Granted Feb 15, 2022·16 cites·28 claims
- 0796US11718678B2Method for altering plasma retention and immunogenicity of antigen-binding moleculeCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Granted Aug 8, 2023·7 cites·16 claims
- 0896US10662245B2Methods of reducing IL-6 activity for disease treatmentCHUGAI PHARMACEUTICAL CO LTD·Filed 2014·Granted May 26, 2020·22 cites·25 claims
- 0994US11046784B2Methods for controlling blood pharmacokinetics of antibodiesIGAWA TOMOYUKI·Filed 2007·Granted Jun 29, 2021·24 cites·50 claims
- 1094US10618965B2Method for altering plasma retention and immunogenicity of antigen-binding moleculeIGAWA TOMOYUKI·Filed 2012·Granted Apr 14, 2020·32 cites·33 claims
- 1194US10519229B2Nucleic acids encoding IL-8 antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Dec 31, 2019·22 cites·33 claims
- 1294US8497355B2Anti-glypican-3 antibody having improved kinetics in plasmaIGAWA TOMOYUKI·Filed 2008·Granted Jul 30, 2013·29 cites·16 claims
- 1393US11180548B2Methods of neutralizing IL-8 biological activityCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Granted Nov 23, 2021·6 cites·11 claims
- 1493US8575317B2Anti-NR10 antibody and use thereofKURAMOCHI TAICHI·Filed 2009·Granted Nov 5, 2013·37 cites·14 claims
- 1593US2025101118A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 1692US2025346677A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 1791US9399680B2Nucleic acids encoding anti-NR10 antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2013·Granted Jul 26, 2016·17 cites·37 claims
- 1891US2024301075A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 1991US2025011443A1Method of modifying isoelectric point of antibody via amino acid substitution in cdrCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 2089US9340615B2Anti-AXL antibodyMAEDA ATSUHIKO·Filed 2010·Granted May 17, 2016·23 cites·23 claims
- 2188US2024010738A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 2288US2024294653A1Anti-nr10 antibody and use thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 2386US2023159648A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 2485US10556949B2Antigen-binding molecule inducing immune response to target antigenCHUGAI PHARMACEUTICAL CO LTD·Filed 2012·Granted Feb 11, 2020·8 cites·26 claims
- 2583US2022306755A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2682US2023183363A1Anti-nr10 antibody and use thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2780US2022041741A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 2880US2022389105A1Method of modifying isoelectric point of antibody via amino acid substitution in cdrCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2979US9556264B2Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredientCHUGAI PHARMACEUTICAL CO LTD·Filed 2012·Granted Jan 31, 2017·5 cites·25 claims
- 3074US2020231688A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 3173US2022389118A1Antigen-binding molecule for promoting elimination of antigensCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3273US2021206862A1Anti-il-6 receptor antibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 3368US2020002429A1Anti-nr10 antibody and use thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites
- 3466US12473375B2Methods for controlling blood pharmacokinetics of antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Granted Nov 18, 2025·0 cites·28 claims
- 3566US2011245473A1Anti-IL-6 Receptor AntibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2008·Application pending·0 cites
- 3666US2011129459A1Anti-nr10 antibody and use thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2008·Application pending·0 cites
- 3763US2015175704A1Anti-nr10 antibody and use thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2014·Application pending·0 cites
- 3863US2019085085A1Anti-il-6 receptor antibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Application pending·0 cites
- 3963US2012253016A1Antibody molecules that bind to il-6 receptorIGAWA TOMOYUKI·Filed 2012·Application pending·0 cites
- 4062US12371485B2Antigen-binding molecule inducing immune response to target antigenCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Granted Jul 29, 2025·0 cites·22 claims
- 4161US2013317203A1Anti-IL-6 Receptor AntibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2013·Application pending·0 cites
- 4261US2023257470A1Method for altering plasma retention and immunogenicity of antigen-binding moleculeCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 4358US2019112393A1Antigen-binding molecule for promoting elimination of antigensCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Application pending·0 cites
- 4457US2017121412A1Anti-IL-6 Receptor AntibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2016·Application pending·0 cites
- 4556US2014335089A1Antigen-binding molecule for promoting elimination of antigensCHUGAI PHARMACEUTICAL CO LTD·Filed 2012·Application pending·0 cites
- 4656US2013295612A1Anti-glypican-3 antibody having improved kinetics in plasmaCHUGAI PHARMACEUTICAL CO LTD·Filed 2013·Application pending·0 cites
- 4746US2015315278A1Anti-Glypican-3 Antibody Having Improved Kinetics in PlasmaCHUGAI PHARMACEUTICAL CO LTD·Filed 2015·Application pending·0 cites
- 4843US2017129950A1Humanized Anti-Epiregulin Antibody, and Cancer Therapeutic Agent Comprising Said Antibody as Active IngredientCHUGAI PHARMACEUTICAL CO LTD·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Tatsuhiko Tachibana files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →